Funding and Grants

ASTOR wishes to acknowledge the generous support of the Schuman, Pedersen and Silverman families and the Alport Syndrome Foundation 2007 - 2015.


University of Minnesota Graduate School - Grant-in-Aid of Research, Artistry and Scholarship - funding to support ASTOR Research Collaborative Meeting - July, 2009.


ASTOR was awarded a National Institutes of Health National Diabetes and Digestive and Kidney Diseases grant to demonstrate that ASTOR can identify sufficient numbers of males and females with Alport syndrome to participate in clinical trials. Five sites will participate in the study:

  • United States: Alport Syndrome Treatments and Outcomes Registry (ASTOR), a collaborative effort of the University of Minnesota and the University of Utah
  • Canada: University of Toronto and the Hospital for Sick Children
  • China: Peking University First Hospital
  • France: Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et d l'Adulte (MARHEA), located at the Clinique Maurice Lamy Hopital Necker-Enfants Malades, Paris
  • Germany: European Alport Registry, located at University of Göttingen

ASTOR received support from the Kenneth and Claudia Silverman Foundation to study early markers of renal disease progression that can serve as surrogates for hard endpoints like end-stage renal disease, decreased glomerular filtration rate or biopsy-proven fibrosis.

ASTOR formed a research collaboration with the Novartis Institutes for BioMedical Research to develop urinary biomarker assays specific for Alport Syndrome glomerular disease.


ASTOR has formed research collaboration with Regulus Therapeutics, San Diego, CA to conduct a natural history study to observe disease progression, standard of care and to investigate potential biomarker in Alport Syndrome patients.


© 2019 Alport Syndrome Treatments and Outcomes Registry All rights reserved.